Immunocore Holdings plc ADR (IMCR) Implied Volatility Current

Tracking IMCR implied volatility helps you identify when options premiums on Immunocore Holdings plc ADR are historically cheap or expensive, and where the best trades are hiding. Immunocore Holdings plc ADR implied volatility reflects the market's expectation of future price movement: when IMCR IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Immunocore Holdings plc ADR's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For IMCR, tracking metrics like IMCR IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on IMCR signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers.

In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where IMCR implied volatility sits today versus where it has been. Our scanner ranks Immunocore Holdings plc ADR implied volatility against its historical range, surfaces extremes in IMCR IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Immunocore Holdings plc ADR IV is rich or cheap — measure it, then act on it.